Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kereos

Kereos?uq=UG6efJS6
1999 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
2ndary - Private LATEST DEAL TYPE
13 INVESTORS
Description

Developer of a nanoscale drug delivery technology designed to deliver therapeutic drug compounds. The company's nanoscale drug delivery technology makes safe and effective delivery of a broad range of drug compounds to a desired target in the body for the treatment of a variety of diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Primary Office
  • 4041 Forest Park Avenue
  • Saint Louis, MO 63108
  • United States

+1 (314) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kereos’s full profile, request a free trial.

Kereos Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private 000.00 Completed Generating Revenue
9. Later Stage VC 11-Jan-2012 00.000 000.00 Completed Generating Revenue
8. Later Stage VC (Series A2) 11-May-2010 00.000 000.00 000.00 Completed Generating Revenue
7. Debt - General 26-Jun-2009 00000 000.00 Completed Generating Revenue
6. Debt - General 01-Dec-2008 00.000 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 07-Feb-2007 00000 000.00 Completed Generating Revenue
4. Early Stage VC (Series B) 20-May-2005 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2005 00.00 Completed Generating Revenue
2. Early Stage VC (Series A) Completed Startup
1. Seed Round 17-Jul-2001 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Kereos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A2 0,000,000 00.000000 000 00 00 00 00 00.000
Series A1 0,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Kereos Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Missouri Technology Venture Capital Minority 000 0000 000000 0
Advantage Capital (St. Louis) Venture Capital Minority 000 0000 000000 0
180 Degree Capital Venture Capital Minority 000 0000 000000 0
Alafi Capital Company Venture Capital Minority 000 0000 000000 0
Apjohn Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Kereos Executive Team (2)

Name Title Board
Seat
Contact
Info
Gregory Lanza Ph.D Co-Founder & Chief Scientific Officer
John Hefti MD Executive Vice President

Kereos Board Members (6)

Name Representing Role Since Contact
Info
Fred Schwarzer JD Charter Life Sciences Board Member 000 0000
Gary Stevenson MB Venture Partners Board Member 000 0000
John Rice Ph.D Triathlon Medical Ventures Board Member 000 0000
Michael Loberg Ph.D Self Board Member 000 0000
Samuel Wickline MD Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »